{
  "pmcid": "5052188",
  "sha256": "770e4ae4d495be344cabe84272a0e197018bacd999a33aa8818ea7a5dacc08ca",
  "timestamp_utc": "2025-11-09T23:56:03.919003+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.861837633731906,
    "reading_ease": 29.272143906020574,
    "word_count": 227
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Collagenase Clostridium Histolyticum Injection for Adhesive Capsulitis"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive a single injection of 0.5 mL placebo or 0.145, 0.29, or 0.58 mg CCH."
      },
      "Participants": {
        "score": 2,
        "evidence": "60 patients with adhesive capsulitis, diagnosed by restricted active ROM of at least 60° in the affected shoulder."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive a single injection of 0.5 mL placebo or 0.145, 0.29, or 0.58 mg CCH."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the efficacy of collagenase clostridium histolyticum (CCH) injections compared to physical therapy."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was improvement in active forward flexion at 30 days."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "This randomised controlled trial involved 60 patients with adhesive capsulitis."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "CCH at 0.58 mg/1 mL and 0.58 mg/2 mL demonstrated superior improvement in active forward flexion compared to exercise alone (mean difference: 26° and 31°, p = 0.03 and p = 0.01, respectively)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not disclosed."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}